Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Salt-Water Solution to Improve Symptoms in Concussion

This study has been completed.
Sponsor:
Information provided by:
Rady Children's Hospital, San Diego
ClinicalTrials.gov Identifier:
NCT00142090
First received: September 1, 2005
Last updated: February 2, 2009
Last verified: January 2009
  Purpose

The purpose of this study is to find out if 3% hypertonic saline (salt-water solution) given in a vein improves the headache that may be caused by a concussion. 3% hypertonic saline may also improve some of the other symptoms that may be caused by concussion (for example: confusion, nausea, vomiting).

This research is being done because there have been previous experience which suggests that 3% hypertonic saline has been beneficial in the treatment of children with more severe brain injury.


Condition Intervention
Brain Concussion
Post-Concussion Symptoms
Drug: 3% Hypertonic saline
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Use of 3% Hypertonic Saline to Improve Clinical Symptoms in Concussed Patients

Resource links provided by NLM:


Further study details as provided by Rady Children's Hospital, San Diego:

Primary Outcome Measures:
  • Improvement in headache.

Secondary Outcome Measures:
  • Improvement in other clinical symptoms of concussion (decrease level of GCS, nausea, vomiting, inability to recall events, repetitive questioning, and disorientation to person, place, and time).

Enrollment: 8
Study Start Date: November 2004
Study Completion Date: July 2007
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 2
3% Hypertonic saline
Drug: 3% Hypertonic saline
Placebo Comparator: 1
Normal saline
Drug: Placebo
Normal saline

  Hide Detailed Description

Detailed Description:

A concussion is formally described as a clinical syndrome characterized by immediate and transient changes in brain function including alteration of mental status and level of consciousness, resulting from mechanical force or trauma. Despite its prevalence, its pathophysiology remains a mystery as does its spectrum of clinical presentation.

A concussion, sometimes described as a mild traumatic brain injury (TBI), can often present with initial loss of consciousness, change in behavior, confusion, amnesia, or aphasia which all result in a Glasgow Coma Scale (GCS) that is less than normal. As the time from the initial injury lengthens, these symptoms can progressively worsen and new symptoms such as vomiting and headaches can also develop. Usually, there is no evidence of a significant intracranial injury by computed tomography (CT) imaging and these symptoms often improve with a gradual progression towards a normal neurologic baseline; in fact, the risk of complication in this population is very rare. The time for this improvement varies greatly and can occur over a period ranging from hours to days. During this transient time, the patient is often very uncomfortable due to persistent headaches, inability to tolerate oral intake due to nausea and/or vomiting, confusion, and episodes of amnesia. In some instances, the combative behavior of the patient can be difficult to tolerate both by the family and the medical staff.

Just as the symptoms caused by a concussion vary greatly in presentation and duration, so do the theories behind the pathophysiology of mild TBI. The transient loss of cerebral function after a head injury was formally differentiated from severe head injury for the first time by the Persian physician Rhazes in 900 AD and has since caused much speculation and varying clinical descriptions throughout history. It took another 500 years before a "commotion" or shaking of the brain was theorized to be responsible for clinical signs. Presently, the exact cause of concussive symptoms continue to remain an enigma; a major question however, is whether a concussion is due to a lesser degree of diffuse structural change seen in severe traumatic brain injury, or if it is in fact a mechanism caused by reversible functional changes of the neurons and axons.

Animal models have demonstrated altered metabolic profiles of the brain tissue which resolves within hours of initial insult. Other animal models have demonstrated a change in the integrity of the microvascular endothelium after TBI. It can be hypothesized that there are areas of "microcontusion" and pericontusional edema that maybe responsible for alterations in brain chemistry which may ultimately lead to the clinical symptoms associated with mild TBI. Multiple other studies have theorized that the direct and indirect effects of trauma on cerebral vasculature may lead to a vasoconstrictive phenomenon that may be responsible for postconcussive symptoms.

Currently, the management of patients with mild traumatic brain injuries includes observation and symptomatic therapies including analgesia without obscuring a neurologic exam (acetaminophen) and antiemetic measures (ondansetron). While many patients are often discharged home after initial evaluation in the Emergency Department, some are admitted to the hospital for supportive care. The symptoms may resolve in a period of hours to days.

There has been substantial retrospective data and limited prospective data in children which suggests that hypertonic saline (HTS) can improve the control of intracranial pressure (ICP) in patients with acute brain injury. In 1992, a report published by the Journal of Neurosurgical Anesthesiology indicated that HTS reduced elevated ICP in children after head injury. This study looked at a single intravenous bolus of HTS in comparison to the same volume of normal saline and demonstrated a clear difference. Subsequently, it was demonstrated that HTS appears to be efficacious in controlling ICP. In a retrospective chart review, 68 children with closed head injury were cared for using a standardized protocol and the intravenous infusion of 3% HTS in quantities designed to drive the serum sodium to levels that would reduce the ICP to less than 20 mmHg. Of the patients in who HTS was used, only 3 patients (4%) died of uncontrolled ICP. Of note, there were no adverse effects of super-physiologic hyperosmolarity such as renal failure, pulmonary edema, or central pontine demyelination.

The use of 3% hypertonic saline in traumatic brain injury has recently been investigated by many centers and is now included as first tier therapy in the management of decreasing intracranial pressure (ICP) secondary to severe traumatic brain injury in the pediatric population. Its mechanism in ICP reduction lies in its favorable rheologic and osmolar gradient effects; it concomitantly augments intravascular volume and increase mean arterial pressure to provide optimum cerebral perfusion pressure. Again, multiple studies have shown the direct effect of HTS in lowering ICP along with its safety in a pediatric population. HTS has also been used to treat altered mental status in diabetic ketoacidosis.

Many of the symptoms associated with mild traumatic brain injury may be due to mild elevations in intracranial pressure, minimal cerebral edema, and/or vasospasm of the cerebral vasculature. Hypertonic saline may be instrumental in improving the symptoms of concussion by addressing the commonly suspected mechanisms responsible for these symptoms. By reducing mild cerebral edema and/or improving cerebral perfusion pressure, cerebral vasospasm may be overcome by reversal or by improved flow; thus, 3% HTS may allow favorable treatment of postconcussive symptoms.

  Eligibility

Ages Eligible for Study:   6 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Greater than or equal to 6 years of age
  • Admitted for observation of closed head injury
  • GCS greater than or equal to 13
  • Presence of headache
  • CT scan showing no brain injury or only a small contusion (an area of low attenuation less than 10 mm or a punctuate area of high attenuation with surrounding edema less than 5mm). CT evidence of high or mixed attenuation would be consistent with a hemorrhagic lesion and therefore not qualify to participate in the study. Evidence of skull fractures and cephalohematomas on CT would not exclude the patient from the study.

Exclusion Criteria:

  • Age less than 6
  • GCS less than 13
  • Radiographic evidence of extra-axial blood or subarachnoid blood
  • Possible or witnessed posttraumatic seizure
  • Developmental delay/ mental retardation
  • Underlying cardiac or renal pathology
  • Suspected and/or documented use of alcohol and/or illicit substances
  • Medication history which includes administration of acetaminophen within 4 hours prior to enrollment or chronic anticoagulant use (ie: Coumadin, Aspirin
  • Associated injuries requiring the use of narcotics for analgesia (ie: long bone injuries, deep laceration repair)
  • Intubation
  • Non-English speaking
  • No parental consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00142090

Locations
United States, California
Children's Hospital San Diego
San Diego, California, United States, 92123
Sponsors and Collaborators
Rady Children's Hospital, San Diego
Investigators
Principal Investigator: Karim T Rafaat, MD Rady Children's Hospital, San Diego
Study Director: Bradley M Peterson, MD Rady Children's Hospital, San Diego
  More Information

No publications provided

Responsible Party: Division of Pediatric Critical Care, Rady Children's Hospital, San Diego
ClinicalTrials.gov Identifier: NCT00142090     History of Changes
Other Study ID Numbers: 04139-C, 11266
Study First Received: September 1, 2005
Last Updated: February 2, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Rady Children's Hospital, San Diego:
Brain Concussion
Post-Concussion Syndrome
Closed Head Injury
Traumatic Brain Injury
Hypertonic Saline Solution

Additional relevant MeSH terms:
Brain Concussion
Post-Concussion Syndrome
Brain Diseases
Brain Injuries
Central Nervous System Diseases
Craniocerebral Trauma
Head Injuries, Closed
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries
Wounds, Nonpenetrating

ClinicalTrials.gov processed this record on November 25, 2014